docetaxel + fulvestrant

Docetaxel + fulvestrant is a combination therapy consisting of two distinct drugs used in the treatment of estrogen receptor (ER)-positive breast cancer. Docetaxel is a taxane-class chemotherapeutic agent that inhibits cell division by stabilizing microtubules, leading to apoptosis in rapidly dividing cells. Fulvestrant is an estrogen receptor antagonist that binds, blocks, and accelerates degradation of the estrogen receptor, thereby inhibiting estrogen-driven tumor growth. Preclinical studies have demonstrated that this combination has synergistic antitumor effects both in vitro and in vivo for ER-positive breast cancer models, likely due to complementary mechanisms—docetaxel’s cytotoxicity and fulvestrant’s hormonal blockade[1][2][3]. This regimen may be considered for patients with hormone receptor-positive advanced or metastatic breast cancer who require both endocrine therapy and chemotherapy.